NYSE - Nasdaq Real Time Price USD

Dr. Reddy's Laboratories Limited (RDY)

71.75 -0.40 (-0.55%)
As of 12:54 PM EDT. Market Open.
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
271,302,000.00
245,879,000.00
214,391,000.00
189,722,000.00
Cost of Revenue
113,181,000.00
106,536,000.00
100,551,000.00
86,645,000.00
Gross Profit
158,121,000.00
139,343,000.00
113,840,000.00
103,077,000.00
Operating Expense
93,032,000.00
80,289,000.00
77,921,000.00
70,167,000.00
Operating Income
65,089,000.00
59,054,000.00
35,919,000.00
32,910,000.00
Net Non Operating Interest Income Expense
633,000.00
-248,000.00
7,000.00
-144,000.00
Other Income Expense
3,387,000.00
1,561,000.00
-3,628,000.00
-6,353,000.00
Pretax Income
69,109,000.00
60,367,000.00
32,298,000.00
26,413,000.00
Tax Provision
16,903,000.00
15,300,000.00
8,730,000.00
9,175,000.00
Net Income Common Stockholders
52,206,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Diluted NI Available to Com Stockholders
52,206,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Basic EPS
313.91
271.43
142.08
103.94
Diluted EPS
313.29
270.85
141.69
103.65
Basic Average Shares
166,289.11
166,034.89
165,882.70
165,844.34
Diluted Average Shares
166,618.74
166,388.17
166,338.63
166,316.04
Total Operating Income as Reported
65,150,000.00
57,144,000.00
29,476,000.00
24,280,000.00
Total Expenses
206,213,000.00
186,825,000.00
178,472,000.00
156,812,000.00
Net Income from Continuing & Discontinued Operation
52,206,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Normalized Income
49,789,426.27
44,173,750.00
26,729,630.00
21,679,450.00
Interest Income
2,105,000.00
1,180,000.00
965,000.00
826,000.00
Interest Expense
1,472,000.00
1,428,000.00
958,000.00
970,000.00
Net Interest Income
633,000.00
-248,000.00
7,000.00
-144,000.00
EBIT
70,581,000.00
61,795,000.00
33,256,000.00
27,383,000.00
EBITDA
84,898,000.00
74,431,000.00
45,080,000.00
40,179,000.00
Reconciled Cost of Revenue
113,181,000.00
106,536,000.00
100,551,000.00
86,645,000.00
Reconciled Depreciation
14,317,000.00
12,636,000.00
11,824,000.00
12,796,000.00
Net Income from Continuing Operation Net Minority Interest
52,206,000.00
45,067,000.00
23,568,000.00
17,238,000.00
Total Unusual Items Excluding Goodwill
3,199,000.00
1,191,000.00
-4,331,000.00
-6,833,000.00
Total Unusual Items
3,199,000.00
1,191,000.00
-4,331,000.00
-6,833,000.00
Normalized EBITDA
81,699,000.00
73,240,000.00
49,411,000.00
47,012,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
782,426.27
297,750.00
-1,169,370.00
-2,391,550.00
3/31/2021 - 4/11/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LFCR Lifecore Biomedical, Inc.
6.41
+1.83%
 
PETQ PetIQ, Inc.
16.61
+0.58%
 
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,484.65
-3.60%
 
PBH Prestige Consumer Healthcare Inc.
71.22
+2.04%
 
HLN Haleon plc
8.42
+0.67%
 
INDV Indivior PLC
18.70
+0.86%
 
PCRX Pacira BioSciences, Inc.
26.89
+3.03%
 
NBIX Neurocrine Biosciences, Inc.
139.61
+4.45%
 
AMRX Amneal Pharmaceuticals, Inc.
5.44
+1.30%
 
NATCOPHARM.NS NATCO Pharma Limited
1,022.80
+1.70%